BIIB biotech catalysts & pipeline

BIOGEN INC · Data as of 2026-10-25

Upcoming catalysts

litifilimab — Clinical data readout

Late 2026

• Registrational data for litifilimab in SLE expected by end of 2026 and additional Phase 3 readouts for litifilimab in CLE, felzartamab in AMR, and zorevunersen in Dravet syndrome anticipated next year

Source filing

felzartamab — Clinical data readout

in H1 2027

Data from the TRANSCEND study is expected in H1 2027.

Source filing

litifilimab — Clinical data readout

2027

Registrational data for litifilimab in SLE expected by end of 2026 and additional Phase 3 readouts for litifilimab in CLE, felzartamab in AMR, and zorevunersen in Dravet syndrome anticipated next year

Source filing

zorevunersen — Clinical data readout

2027

Registrational data for litifilimab in SLE expected by end of 2026 and additional Phase 3 readouts for litifilimab in CLE, felzartamab in AMR, and zorevunersen in Dravet syndrome anticipated next year

Source filing

Explore the free biotech catalyst calendar